Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®

NCT ID: NCT02019433

Last Updated: 2017-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Implant Survival as well as clinical and radiological Follow-Up of acetabular Titan-Augment Structan®

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Hip Arthroplasty Revision

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Structan®

Structan®

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Structan®

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minimum age 18 years
* Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment
* Patient consent for study participation
* Physical and mental willingness to participate in the follow-ups

Exclusion Criteria

* Patient not available for follow-up
* Increased anesthetics risks for the patient according to the "American Society of Anesthesiology": ASA IV
* Tumor
* Alcohol- or Drug abuse
* Permanent cortisone therapy
* Clinically relevant infection
* (Planned) pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aesculap AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite Campus Berlin Mitte

Berlin, , Germany

Site Status

Klinik am Eichert

Göppingen, , Germany

Site Status

St. Remigius Krankenhaus Opladen

Leverkusen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AAG-O-H-1212

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PMCF 8 Year Results TRJ®
NCT04542174 COMPLETED
CoreHip - Post Market Clinical Follow-Up Study
NCT03685110 ACTIVE_NOT_RECRUITING